Skip to content

Warby Parker WRBY Committed amount of research and development costs

Committed amount of research and development costs at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$39.94M-11.2%
Immunome logo
ImmunomeIMNM
$986K
Lantheus Holdings logo
Lantheus HoldingsLNTH
$1.45M
Q2 Holdings logo
Q2 HoldingsQTWO
2.3%
Viatris logo
ViatrisVTRS
$248.6M+12.0%
Alumis Inc. logo
Alumis Inc.ALMS
$3.35M-74.0%

Other financials

Income statement

See full
Revenue$242.4M+8.3%
Gross profit$131.0M+4.0%
Operating income$1.7M-32.5%
Net income$3.2M-8.5%
EPS (diluted)$0.030.0%

Balance sheet

See full
Cash & equivalents$288.2M+8.7%
Total debt$237.6M+6.2%
Total equity$375.8M+6.1%
Total assets$736.4M+7.9%

Cash flow

See full
Operating cash flow$24.5M-16.5%
CapEx$16.1M-0.1%
Free cash flow$8.4M-36.6%

Valuation

See full
Market cap$3.15B+17.1%

Profitability

See full
Gross margin53.4%-1.8pp
Operating margin-0.7%-0.3pp
Net margin0.1%0.0pp
FCF margin4.5%-0.8pp

Returns & leverage

See full
Return on equity0.2%+0.1pp
Debt / equity0.6×0.0×
Current ratio2.3×-0.4×

Where this comes from

Reported directly by Warby Parker in its filing.

Tagged under the XBRL concept wrby:CollaborativeArrangementCommittedAmountOfResearchAndDevelopmentCostsToBeReceived.

The official record: Warby Parker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Warby Parker's committed amount of research and development costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Warby Parker's committed amount of research and development costs?
Warby Parker (WRBY) reported committed amount of research and development costs of $75M in Q1 2026.
What does committed amount of research and development costs mean?
This represents the contractual obligation to fund research and development activities under collaborative agreements with third-party partners. It highlights the company's commitment to innovation and product pipeline expansion through external partnerships. Monitoring this helps assess future cash outflows related to strategic R&D initiatives.